Your browser doesn't support javascript.
loading
Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.
Mantovani, Giovanna; Bastepe, Murat; Monk, David; de Sanctis, Luisa; Thiele, Susanne; Usardi, Alessia; Ahmed, S Faisal; Bufo, Roberto; Choplin, Timothée; De Filippo, Gianpaolo; Devernois, Guillemette; Eggermann, Thomas; Elli, Francesca M; Freson, Kathleen; García Ramirez, Aurora; Germain-Lee, Emily L; Groussin, Lionel; Hamdy, Neveen; Hanna, Patrick; Hiort, Olaf; Jüppner, Harald; Kamenický, Peter; Knight, Nina; Kottler, Marie-Laure; Le Norcy, Elvire; Lecumberri, Beatriz; Levine, Michael A; Mäkitie, Outi; Martin, Regina; Martos-Moreno, Gabriel Ángel; Minagawa, Masanori; Murray, Philip; Pereda, Arrate; Pignolo, Robert; Rejnmark, Lars; Rodado, Rebecca; Rothenbuhler, Anya; Saraff, Vrinda; Shoemaker, Ashley H; Shore, Eileen M; Silve, Caroline; Turan, Serap; Woods, Philip; Zillikens, M Carola; Perez de Nanclares, Guiomar; Linglart, Agnès.
Afiliação
  • Mantovani G; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Bastepe M; Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Monk D; Imprinting and Cancer Group, Cancer Epigenetic and Biology Program (PEBC), Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Barcelona, Spain.
  • de Sanctis L; Pediatric Endocrinology Unit, Department of Public Health and Pediatric Sciences, University of Torino, Turin, Italy.
  • Thiele S; Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Lübeck, Lübeck, Germany.
  • Usardi A; APHP, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Platform of Expertise Paris-Sud for Rare Diseases and Filière OSCAR, Bicêtre Paris Sud Hospital (HUPS), Le Kremlin-Bicêtre, France.
  • Ahmed SF; APHP, Endocrinology and diabetes for children, Bicêtre Paris Sud Hospital (HUPS), Le Kremlin-Bicêtre, France.
  • Bufo R; Developmental Endocrinology Research Group, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK.
  • Choplin T; IPOHA, Italian Progressive Osseous Heteroplasia Association, Cerignola, Foggia, Italy.
  • De Filippo G; K20, French PHP and related disorders patient association, Jouars Pontchartrain, France.
  • Devernois G; APHP, Department of medicine for adolescents, Bicêtre Paris Sud Hospital (HUPS), Le Kremlin-Bicêtre, France.
  • Eggermann T; K20, French PHP and related disorders patient association, Jouars Pontchartrain, France.
  • Elli FM; Institute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Freson K; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • García Ramirez A; Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, Gasthuisberg, University of Leuven, Leuven, Belgium.
  • Germain-Lee EL; AEPHP, Spanish PHP and related disorders patient association, Huércal-Overa, Almería, Spain.
  • Groussin L; Albright Center & Center for Rare Bone Disorders, Division of Pediatric Endocrinology & Diabetes, Connecticut Children's Medical Center, Farmington, CT, USA.
  • Hamdy N; Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA.
  • Hanna P; APHP, Department of Endocrinology, Cochin Hospital (HUPC), Paris, France.
  • Hiort O; University of Paris Descartes, Sorbonne Paris Cité, Paris, France.
  • Jüppner H; Department of Medicine, Division of Endocrinology and Centre for Bone Quality, Leiden University Medical Center, Leiden, Netherlands.
  • Kamenický P; INSERM U1169, Bicêtre Paris Sud, Paris Sud - Paris Saclay University, Le Kremlin-Bicêtre, France.
  • Knight N; Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Lübeck, Lübeck, Germany.
  • Kottler ML; Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
  • Le Norcy E; APHP, Reference Center for Rare Disorders of Calcium and Phosphate Metabolism, Platform of Expertise Paris-Sud for Rare Diseases and Filière OSCAR, Bicêtre Paris Sud Hospital (HUPS), Le Kremlin-Bicêtre, France.
  • Lecumberri B; APHP, Department of Endocrinology and Reproductive Diseases, Bicêtre Paris Sud Hospital (HUPS), Le Kremlin-Bicêtre, France.
  • Levine MA; INSERM U1185, Paris Sud - Paris Saclay University, Le Kremlin-Bicêtre, France.
  • Mäkitie O; UK acrodysostosis patients' group, London, UK.
  • Martin R; Department of Genetics, Reference Centre for Rare Disorders of Calcium and Phosphate Metabolism, Caen University Hospital, Caen, France.
  • Martos-Moreno GÁ; BIOTARGEN, UNICAEN, Normandie University, Caen, France.
  • Minagawa M; University of Paris Descartes, Sorbonne Paris Cité, Paris, France.
  • Murray P; APHP, Department of Odontology, Bretonneau Hospital (PNVS), Paris, France.
  • Pereda A; Department of Endocrinology and Nutrition, La Paz University Hospital, Madrid, Spain.
  • Pignolo R; Department of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain.
  • Rejnmark L; Endocrine Diseases Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
  • Rodado R; Division of Endocrinology and Diabetes and Center for Bone Health, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Rothenbuhler A; Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Saraff V; Osteometabolic Disorders Unit, Hormone and Molecular Genetics Laboratory (LIM/42), Endocrinology Division, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
  • Shoemaker AH; Department of Endocrinology, Hospital Infantil Universitario Niño Jesús, CIBERobn, ISCIII, Madrid, Spain.
  • Shore EM; Department of Pediatrics, Autonomous University of Madrid (UAM), Madrid, Spain.
  • Silve C; Endocrine Diseases Research Group, Hospital La Princesa Institute for Health Research (IIS La Princesa), Madrid, Spain.
  • Turan S; Division of Endocrinology, Chiba Children's Hospital, Chiba, Japan.
  • Woods P; Department of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  • Zillikens MC; Molecular (Epi)Genetics Laboratory, BioAraba National Health Institute, Hospital Universitario Araba-Txagorritxu, Vitoria-Gasteiz, Alava, Spain.
  • Perez de Nanclares G; Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Linglart A; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Nat Rev Endocrinol ; 14(8): 476-500, 2018 08.
Article em En | MEDLINE | ID: mdl-29959430
ABSTRACT
This Consensus Statement covers recommendations for the diagnosis and management of patients with pseudohypoparathyroidism (PHP) and related disorders, which comprise metabolic disorders characterized by physical findings that variably include short bones, short stature, a stocky build, early-onset obesity and ectopic ossifications, as well as endocrine defects that often include resistance to parathyroid hormone (PTH) and TSH. The presentation and severity of PHP and its related disorders vary between affected individuals with considerable clinical and molecular overlap between the different types. A specific diagnosis is often delayed owing to lack of recognition of the syndrome and associated features. The participants in this Consensus Statement agreed that the diagnosis of PHP should be based on major criteria, including resistance to PTH, ectopic ossifications, brachydactyly and early-onset obesity. The clinical and laboratory diagnosis should be confirmed by a molecular genetic analysis. Patients should be screened at diagnosis and during follow-up for specific features, such as PTH resistance, TSH resistance, growth hormone deficiency, hypogonadism, skeletal deformities, oral health, weight gain, glucose intolerance or type 2 diabetes mellitus, and hypertension, as well as subcutaneous and/or deeper ectopic ossifications and neurocognitive impairment. Overall, a coordinated and multidisciplinary approach from infancy through adulthood, including a transition programme, should help us to improve the care of patients affected by these disorders.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio Paratireóideo / Pseudo-Hipoparatireoidismo / Guias de Prática Clínica como Assunto / Diagnóstico Tardio Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies Limite: Female / Humans / Male / Newborn Idioma: En Revista: Nat Rev Endocrinol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio Paratireóideo / Pseudo-Hipoparatireoidismo / Guias de Prática Clínica como Assunto / Diagnóstico Tardio Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies Limite: Female / Humans / Male / Newborn Idioma: En Revista: Nat Rev Endocrinol Ano de publicação: 2018 Tipo de documento: Article